SLC7A11 and glioma: As seizures are common in glioma patients, sulfasalazine, an FDA-approved potent but short-term inhibitor of SLC7A11 commonly prescribed to inflammatory bowel disease patients to alleviate colonic inflammation reduced glutamate excitotoxicity and seizures in a pilot study involving nine glioma patients [74].